Manager TitleAgeSince
President - 2023-12-13
Corporate Officer/Principal 57 -
Corporate Secretary - -
Director TitleAgeSince
Director/Board Member 57 2023-12-13
Director/Board Member - 2023-12-13
Date Insider Type Main position Quantity % Market Cap. Importance
12/14/23 Issuer sale

Director

127,934 0.0678%
12/14/23 Issuer sale

Chief Executive Officer

643,595 0.3411%
12/14/23 Issuer sale

Director

97,934 0.0519%
Change 5-day change 1-year change 3-year change Capi.($)
-0.07%+4.77% - - 43.15B
-0.21%-4.43%+44.40%+74.13% 66.22B
-3.22%+0.66%+7.67%+69.35% 55.2B
+0.90%+4.17%+12.32%+92.00% 52.79B
+3.28%+5.58%+26.51%+50.05% 45.53B
+0.51%+9.95%+22.40%+133.92% 43.94B
-1.15%+0.39%+263.21%+594.60% 41.64B
+0.10%+9.90%+16.11%+59.33% 34B
-8.38%-6.95%+26.35%-1.93% 25.84B
+0.76%+4.47%+37.60%+27.45% 23.51B
Average -1.02%+4.07%+50.73%+122.10% 43.19B
Weighted average by Cap. -0.78%+3.72%+49.60%+126.41%
Logo Seagen Inc.
Seagen Inc. est spécialisé dans le développement et la commercialisation de thérapies à base d'anticorps monoclonaux destinées au traitement du cancer. Le CA par source de revenus se répartit comme suit : - ventes de produits (87%) ; - royalties (8,4%) ; - revenus issus d'accords de collaboration et de licence (4,6%).
Employees
3,256
  1. Stock Market
  2. Stocks
  3. SGEN Stock